Lenoss Medical received notice of allowance for two new U.S. patents and the grant of one European patent, further extending the company’s patent protection of the OsteoPearl Biological Allograft implant design and associated surgical instrumentation. Over the past three years, Lenoss has been granted six patents for the OsteoPearl implant and surgical instruments. These new patents bring the Lenoss portfolio to 23 granted patents in total.
The OsteoPearl implant is a novel biological allograft implant designed to augment painful osteoporotic vertebral compression fractures by providing a natural scaffold for physiological fracture repair.
“Securing these patents is more than just expanding our IP portfolio—it underscores Lenoss Medical’s role in redefining how spinal fractures are treated,” said Dom Messerli, CEO and Founder of Lenoss Medical, Inc. “This protection not only validates the uniqueness of our OsteoPearl® technology, but also strengthens our ability to bring a truly natural, patient-centered solution to market. With a solid foundation of innovation, we are well-positioned to scale our commercialization, forge strategic partnerships, and transform the standard of care for vertebral compression fractures.”
Lenoss Medical received notice of allowance for two new U.S. patents and the grant of one European patent, further extending the company’s patent protection of the OsteoPearl Biological Allograft implant design and associated surgical instrumentation. Over the past three years, Lenoss has been granted six patents for the OsteoPearl implant and...
Lenoss Medical received notice of allowance for two new U.S. patents and the grant of one European patent, further extending the company’s patent protection of the OsteoPearl Biological Allograft implant design and associated surgical instrumentation. Over the past three years, Lenoss has been granted six patents for the OsteoPearl implant and surgical instruments. These new patents bring the Lenoss portfolio to 23 granted patents in total.
The OsteoPearl implant is a novel biological allograft implant designed to augment painful osteoporotic vertebral compression fractures by providing a natural scaffold for physiological fracture repair.
“Securing these patents is more than just expanding our IP portfolio—it underscores Lenoss Medical’s role in redefining how spinal fractures are treated,” said Dom Messerli, CEO and Founder of Lenoss Medical, Inc. “This protection not only validates the uniqueness of our OsteoPearl® technology, but also strengthens our ability to bring a truly natural, patient-centered solution to market. With a solid foundation of innovation, we are well-positioned to scale our commercialization, forge strategic partnerships, and transform the standard of care for vertebral compression fractures.”
Copy to clipboard 
